# CoLucid Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/colucid-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Cambridge, US
- Total disclosed funding: $87M
- Latest round: Series C (Jan 13, 2015)
- Investors on record: 10

## About

Founded in 2005 and based in the US, CoLucid Pharmaceuticals, Inc. operates as a biopharmaceutical company that develops remedies for migraines.

## Funding rounds

- Series C, Jan 13, 2015, $37M — Auriga Partners, Care Capital, Domain Associates, TVM Capital Life Science, Pappas Capital, Triathlon Medical Partners, Novo Holdings, Pearl Street Venture Funds
- Series B, Jul 1, 2008, $25M — Care Capital, Domain Associates, Pappas Capital, Triathlon Medical Partners, Pearl Street Venture Funds
- Series A, Jan 17, 2006, $17M — Domain Associates, Pappas Capital, Triathlon Medical Partners, Pearl Street Venture Funds
- Series A, Dec 31, 2005, $8.3M — Domain Associates, Pappas Capital, Triathlon Medical Partners, MPM BioImpact, Eli Lilly & Company

## Investors

- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Series A, Series B, Series C
- Pappas Capital (https://capitalatlas.ai/funds/pappas-capital) — Series A, Series B, Series C
- Triathlon Medical Partners (https://capitalatlas.ai/funds/triathlon-medical-partners) — Series A, Series B, Series C
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series A
- Eli Lilly & Company — Series A
- Pearl Street Venture Funds (https://capitalatlas.ai/funds/pearl-street-venture-funds) — Series A, Series B, Series C
- Care Capital (https://capitalatlas.ai/funds/care-capital) — Series B, Series C
- Auriga Partners (https://capitalatlas.ai/funds/auriga-partners) — Series C
- TVM Capital Life Science (https://capitalatlas.ai/funds/tvm-capital-life-science) — Series C
- Novo Holdings — Series C